EMA Qualifies Big MS Data Network for Post-Authorization Safety Studies

The Multiple Sclerosis Data Network has received formal qualification as a reliable data source for post-authorisation safety studies on disease modifying therapies in multiple sclerosis, provided a common data model is applied. This determination draws on coverage of roughly 360,000 patients across six national and international registries, along with proven ability to record essential safety variables. A study-specific feasibility check is still required for each research question to confirm suitability.

Qualification of Multiple Sclerosis Data Network for Safety Evaluations

The qualification process followed a core protocol developed with marketing authorisation holders to standardise safety outcome measurement and adjustment for confounding factors. Adoption of the common data model converts registry information into a uniform format that supports either meta-analysis of aggregated findings or federated analysis without pooling raw data. Annual life-cycle management reports will monitor performance through statistics on data quality, eligible populations, and adverse event capture rates, ensuring the Multiple Sclerosis Data Network maintains regulatory standards over time.

Completeness Patterns Across Participating Registries

Mandatory variables such as demographics, diagnosis, disease modifying therapy exposure, and prespecified serious adverse events show high completeness. In contrast, medical history, comorbidities, and concomitant medications exhibit lower completeness levels. Linkage to national databases in the Danish Multiple Sclerosis Registry and Swedish Multiple Sclerosis Registry offsets underreporting from direct physician-patient interactions and supplies supplementary outcome information. National coverage supports generalisability to European populations receiving active treatment, although pregnancy-related data and certain effectiveness measures vary and require individual assessment for each study.

Ad

Integration into European Risk Management Planning

The qualification allows marketing authorisation holders to utilise this multi-country resource when meeting post-authorisation safety study obligations under European Union risk management plans. Large sample sizes enable investigation of infrequent adverse events, while the common data model lowers technical barriers to cross-registry work. Continued refinement of external linkages and the common data model will shape the network’s ability to address new regulatory questions on disease modifying therapies. Further details appear in the draft qualification opinion issued by the European Medicines Agency. These developments position the Multiple Sclerosis Data Network as an evolving asset for long-term pharmacovigilance in multiple sclerosis care.